Loading…
The treatment was conducted under FDA's Expanded Access Authorization.
Adagio Medical Holdings, Inc. (Nasdaq: ADGM) announced that it has treated the first patient using its vCLAS Ultra Ultra-Low Temperature Ablation System. This treatment was performed under the U.S. Food and Drug Administration's (FDA) Expanded Access Authorization.
The vCLAS Ultra System is designed for use in cardiac ablation procedures. Adagio Medical's announcement signifies a significant step in the clinical application of this technology.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.